Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$570K Buy
4,434
+758
+21% +$88.7K 0.05% 120
2026
Q1
$442K Sell
3,676
-50
-1% -$5.77K 0.05% 114
2025
Q4
$392K Buy
3,726
+58
+2% +$5.45K 0.04% 115
2025
Q3
$308K Buy
3,668
+53
+1% +$4.37K 0.04% 138
2025
Q2
$286K Sell
3,615
-44
-1% -$3.5K 0.04% 138
2025
Q1
$328K Buy
3,659
+291
+9% +$27.2K 0.05% 128
2024
Q4
$335K Buy
3,368
+86
+3% +$8.87K 0.05% 120
2024
Q3
$373K Sell
3,282
-177
-5% -$21K 0.06% 107
2024
Q2
$428K Buy
3,459
+136
+4% +$17.5K 0.07% 90
2024
Q1
$438K Sell
3,323
-35
-1% -$4.31K 0.07% 89
2023
Q4
$366K Sell
3,358
-58
-2% -$6.02K 0.06% 127
2023
Q3
$352K Sell
3,416
-310
-8% -$33.4K 0.07% 94
2023
Q2
$430K Sell
3,726
-234
-6% -$26.6K 0.09% 81
2023
Q1
$421K Buy
3,960
+118
+3% +$12.7K 0.09% 81
2022
Q4
$426K Buy
+3,842
New +$393K 0.1% 82

Other funds holding MRK

Goldstein Advisors's MRK Position: Q2 2026 in Review

Goldstein Advisors increased its Merck (MRK) stake by 21% in Q2 2026, buying an estimated $88.7K and bringing the position to 4,434 shares worth $570K. The position accounts for 0.05% of the portfolio, ranked #120.

Goldstein Advisors first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Goldstein Advisors held 4,434 shares of Merck worth $570K as of Q2 2026.
  • Goldstein Advisors bought 758 Merck shares in Q2 2026, an estimated $88.7K.
  • Merck made up 0.05% of Goldstein Advisors's portfolio in Q2 2026, its #120 holding.
  • Goldstein Advisors first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Goldstein Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.